[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"valve-replacement-surgery\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:valve-replacement-surgery":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,41,79],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":5},"100626140","phase-4-comparison-of-anti-thrombotic-treatments-between-aspirin-and-warfarin-during-initial-six-months-after-bioprpsthetic-heart-valve-replacement-100626140",false,"NCT07431762","Comparison of Anti-Thrombotic Treatments Between Aspirin and Warfarin During Initial Six Months After Bioprpsthetic Heart Valve Replacement","CONCLAVE","Inclusion Criteria:\n\n1. Aged ≥ 19 years with successful surgical bioprosthetic valve replacement\n2. Bioprosthetic heart valve in aortic or mitral valve positions, for a day postoperatively\n3. The patient or guardian agrees to the study protocol and the schedule of clinical follow-up, and provides informed, written consent, as approved by the appropriate Institutional Review Board\u002FEthical Committee of the respective clinical site.\n\nExclusion Criteria:\n\n1. Mechanical valve in any heart valve position\n2. Previous hemorrhagic stroke within the last 3 months\n3. Clinically overt stroke within the last 3 months\n4. Current need for anticoagulation (i.e. atrial fibrillation, deep vein thrombosis)\n5. Unstable postoperative conditions at index point (i.e. requirement mechanical hemodynamix support, disabling complications, stroke \\[ischemic, embolic\\], hemorrhagic stroke)\n6. Hypersensitivity to the main component or constituents of aspirin or vitamin K antagonist\n7. Pregnant or lactating women","ALL","19 Years",{"count":19,"type":20},1058,"ESTIMATED","INTERVENTIONAL",[23],"PHASE4","This trial is a multinational, multicenter, randomized, open-label, active-controlled clinical trial comparing the safety of aspirin versus vitamin K antagonists (warfarin) as oral antithrombotic therapy during the initial 6 months following tissue valve replacement (aortic or mitral).",[26],"Valve Replacement Surgery",[28],"aspirin versus vitamin K antagonists","NOT_YET_RECRUITING","2026-02-20",{"date":32,"type":33},"2026-02-25","ACTUAL",{"date":35,"type":20},"2026-02-01",{"date":37,"type":20},"2031-03-31",{"name":39,"class":40},"Asan Medical Center","OTHER",{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":21,"phases":52,"briefSummary":54,"conditions":55,"keywords":62,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":70,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":78},"100626363","phase-3-apixaban-vs-warfarin-in-af-pts-first-three-months-after-repair-or-bio-avr-mvr-100626363","NCT07434661","Apixaban VS Warfarin in AF Pts First Three Months After Repair or BIO AVR MVR","Safety and Efficacy of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation in the First Three Months After Mitral or Aortic Biological Valve Replacement or Repair","SAFE-HEART","Inclusion Criteria:\n\n* Age ≥18 years at the time of enrolment\n* Open heart aortic or mitral valve repair or biological valve replacement in the last 10 days\n* Atrial fibrillation requiring anticoagulation (including pre-existing or post-operative atrial fibrillation),\n* Informed consent from either the patient or a substitute decision-maker.\n\nExclusion Criteria:\n\n* Mechanical valve replacement\n* Antiphospholipid syndrome (triple positive)\n* Severe renal failure (Cockcroft-Gault equation; creatinine clearance \\\u003C15 ml\u002Fmin)\n* Known significant liver disease (Child-Pugh classification B and C)\n* Left ventricular thrombus\n* Ongoing bleeding, hemorrhagic disorders, or bleeding diathesis\n* Known contraindication for any DOAC or VKA\n* Women who are pregnant, breastfeeding, or of childbearing potential\n* Follow-up not possible","18 Years",{"count":51,"type":20},120,[53],"PHASE3","SAFE-HEART is a single-centre, randomized controlled trial comparing the safety and efficiency of Apixaban versus Warfarin in the early period (3 months) after repair or bioprosthetics of the mitral and aortic valve cardiac surgery in patients with atrial fibrillation requiring oral anticoagulation.",[56,57,26,58,59,60,61],"Valve Disease, Heart","Atrial Fibrillation (AF)","Aortic Valve Surgery","Mitral Valve Annuloplasty","Mitral Valve Repair","Mitral Valve Surgery",[63,64,65,66,67,68,69],"anticoagulation","bioprosthetics","atrial fibrillation","mitral valve repair","aortic valve repair","Apixaban","Warfarin",{"date":32,"type":33},{"date":72,"type":20},"2026-02",{"date":74,"type":20},"2029-01",{"name":76,"class":77},"Meshalkin Research Institute of Pathology of Circulation","NETWORK",1,{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":16,"minAge":85,"maxAge":86,"enrollmentInfo":87,"targetDuration":4,"studyType":21,"phases":89,"briefSummary":91,"conditions":92,"keywords":93,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":78},"100608733","phase-one-cardiac-rehabilitation-outcomes-post-valve-replacement-surgery-100608733","NCT07205393","Phase One Cardiac Rehabilitation Outcomes Post Valve Replacement Surgery","Inclusion Criteria:\n\n* The inclusion criteria was elective mitral or aortic valve replacement\n* and to be hemodynamically stable to qualify for a structured rehabilitation program.\n* Being able to understand and complete measurements.\n* And provide informed written consent.\n\nExclusion Criteria:\n\n* Patient with ischemic heart disease before surgery.\n* Those with severe musculoskeletal system disorders.\n* Patients who had persistent or paroxysmal atrial fibrillation.\n* Individuals with severe heart failure.\n* uncontrolled arrhythmias.\n* Comorbidity complicating physical activity or other contraindications to phase one cardiac rehabilitation and Patients who underwent an emergency surgical intervention.","40 Years","55 Years",{"count":88,"type":20},60,[90],"NA","Cardiac rehabilitation is a crucial component of postoperative recovery for patients who have received valve replacement surgery. Aim: This study aimed to evaluate the effectiveness of phase one cardiac rehabilitation in improving cardiovascular function, pulmonary capacity, functional ability, and quality of life.",[26],[94,95,96],"Cardiac rehabilitation","Valve replacement","Spirometry measures","RECRUITING","2025-09-30",{"date":100,"type":33},"2025-10-03",{"date":102,"type":33},"2025-01-01",{"date":104,"type":20},"2025-10-20",{"name":106,"class":40},"South Valley University"]